NEWTOWN SQUARE, Penn., Oct. 26, 2020 /PRNewswire/ -- Kibow Biotech, is a pioneering and innovative health supplement company using clinically validated and scientifically documented probiotics, prebiotics, and synbiotics towards various healthcare applications. The company's flagship products Renadyl(TM)(human) and Azodyl(®) (veterinary), marketed internationally for over a decade, are well known and used worldwide. On its 23(rd) anniversary, the company is pleased to announce the introduction of Kibow Biomunity(TM) as an added flagship product. Kibow Biomunity(TM), an all-natural dietary supplement, has been explicitly designed to help modulate and boost the immune system against stressors and environmental pathogens.
Search / 97358 results found Showing: 1-10 of 97358
President Donald Trump and Democratic presidential nominee Joe Biden appeared on CBS News' "60 Minutes." These are the highlights from their i…
PITTSBURGH, Oct. 26, 2020 /PRNewswire/ -- The PNC Financial Services Group, Inc. (NYSE: PNC) announced today that Chairman, President and Chief Executive Officer William S. Demchak will discuss business performance, strategy and banking in a virtual moderated discussion format at 10:30 a.m. (ET) Monday, Nov. 9, at the Bank of America Securities Future of Financial Services Conference.
First of its kind partnership brings together two industry leaders to create new resources for people with diabetes and associated health conditions.
MALVERN, Pa., Oct. 26, 2020 /PRNewswire/ -- LifeScan, a world leader in blood glucose monitoring serving 20 million people with diabetes and the maker of the iconic OneTouch® brand, today announced its partnership with Truepill(TM), the digital health platform powering consumer health experiences through its API-connected infrastructure. The partnership supports LifeScan's strategic move to expand its OneTouch brand offerings beyond diabetes testing supplies to innovative digital wellness offerings for diabetes and related health conditions, including weight loss, fitness, and hypertension. The partnership will launch in November with an eCommerce platform embedded directly in the OneTouch Reveal(TM) mobile app enabling users to buy testing supplies and wellness services from their homes.
Koppers Logo (PRNewsFoto/Koppers Holdings Inc.)
PITTSBURGH, Oct. 26, 2020 /PRNewswire/ -- Koppers Holdings Inc. (NYSE: KOP), an integrated global provider of treated wood products, wood treatment chemicals and carbon compounds, today reported preliminary net income attributable to Koppers for the third quarter of $75.6 million, or $3.53 per diluted share, compared to net income of $19.9 million, or $0.94 per diluted share, in the prior year quarter. Preliminary income from continuing operations attributable to Koppers for the third quarter was $39.1 million, or $1.83 per diluted share, a record quarter, compared to income from continuing operations of $18.3 million, or $0.86 per diluted share, in the prior year quarter. Beginning in 2020, results of Koppers (Jiangsu) Carbon Chemical Company Limited (KJCC) are classified as held for sale and as discontinued operations for the current year as well as the comparable prior year period. As previously announced, the divestiture of KJCC was completed on September 30, 2020, which resulted in a preliminary gain on sale of $35.8 million in the quarter.
PITTSBURGH, Oct. 26, 2020 /PRNewswire/ -- Cipriani & Werner, P.C., one of America's fastest growing law firms, is pleased to announce that John Loyal, former cyber claims manager at Chubb Insurance, has joined the firm's Cyber Practice Group as a Partner and Co-Chair in the Blue Bell, Pennsylvania office.
PLYMOUTH MEETING, Pa., Oct. 26, 2020 /PRNewswire/ -- INOVIO (NASDAQ: INO) announced today that third quarter 2020 financial results will be released after the market close on November 9, 2020. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss financial results and provide a general business update regarding its DNA Medicines Platform, including the company's ongoing vaccine developments for COVID-19.
